Latest Breaking News On - சுகாதாரம் நிதி - Page 8 : comparemela.com

Investegate |BMO Private Eq Trust Announcements | BMO Private Eq Trust: Quarterly NAV and Dividend Announcement

Quarterly results for the three months ended 31 March 2021 (unaudited) · NAV total return per share for the three-month period of -0.3%. · NAV of 480.67p per share as at 31 March 2021. · Quarterly dividend of 4.35p per Ordinary Share. Introduction As at 31 March 2021, the net assets of the Company were £355.4m, giving a Net Asset Value ( NAV ) per share of 480.67p, which taking into account the dividend of 3.99p paid on 29 January 2021, gives a decrease of 0.3% over the quarter. Exchange rate movements reduced the overall valuation by approximately 1.5% over the quarter. With the discount narrowing to 22.6% as at 31 March 2021 the share price total return for the period was an impressive 22.5%. The discount has continued to narrow and is currently 14.9%.

Glasgow cityUnited kingdomUnited statesHamish mairBollington wilsonRosa mexicanoSupplemental fundv inflexionEquity fundInflexion supplemental fundInflexion enterprise fundScott mcellen companyInflexion partnership capitalBritish engineering servicesInvestment businessStock exchangeRegistrar of companies

Duality Biologics Completed $90 Million Series B Financing

Duality Biologics Completed $90 Million Series B Financing News provided by Share this article Share this article PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of $90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested by YUNION Healthcare Fund, Huagai Capital, NRL Capital, Green Pine Capital Partners, and Oriza Holdings, etc. Series A investor WuXi Biologics (2269.HK) continued to increase its stake in this round to accelerate DualityBio s R&D progress leveraging its premier-quality integrated technology platforms. DualityBio has raised more than $120 million since its establishment in January 2020. Major investors in the previous round include King Star Capital, WuXi Biologics, 6 Dimensions Capital, and other investment institutions. The funds raised in this round will be mainly used for

United statesHong kongJohn zhuXianghong linChris chenYi shiHealthcare fundOriza holdingsPrnewswire duality biologics dualitybio or companyLilly asia venturesHuagai capitalGreen pine capital partnersWuxi biologicsKing star capitalNovel modality drugMeet unmet medical

China s Duality Biologics secures $90m in Series B led by Lilly Asia Ventures

China s Duality Biologics secures $90m in Series B led by Lilly Asia Ventures
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

Elpiscience biopharmaGreater bay area homeland development fundHealthcare fundOriza holdingsDuality biologicsLilly asia venturesHuagai capitalGreen pine capital partnersKong listed chineseWuxi biologicsHillhouse capitalஅதிகமானது வளைகுடா பரப்பளவு தாயகம் வளர்ச்சி நிதிசுகாதாரம் நிதிலில்லி ஆசியா முயற்சிகள்பச்சை பைன் மூலதனம் கூட்டாளர்கள்காங் பட்டியலிடப்பட்டுள்ளது சீன

Duality Biologics Completed $90 Million Series B Financing

Duality Biologics Completed $90 Million Series B Financing
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongJohn zhuXianghong linChris chenYi shiHealthcare fundOriza holdingsPrnewswire duality biologics dualitybio or companyLilly asia venturesHuagai capitalGreen pine capital partnersWuxi biologicsKing star capitalNovel modality drugMeet unmet medical

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding News provided by Share this article Share this article SUZHOU, China, May 18, 2021 /PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter GeneQuantum ) announced the completion of Series C fund raising of several hundreds of millions RMB. This series of fund raising is led by China Life Private Equity Investment, jointly by PICC Capital Equity Investment, Sunshine Guojian and Suzhou Wuzhong Biomedicine Industrial Park Investment. The current fund raising will provide a solid financial foundation to GeneQuantum for its global clinical development and pipeline expansion of next generation site-specific bioconjugates. Since its establishment, GeneQuantum has focused on the development of innovative bioconjugate drugs represented by Antibody-Drug-Conjugate (ADC). We possess highly differentiated ADC technology platforms, including enzyme catalyzed site-specific conjugation technology, innovative li

Guo jianGang qinLerming pharmaLeidi zhangInnovation fundHealthcare fundInvestment co ltdGenequantum healthcare suzhou co ltdRendong holdingSuzhou direct investment fundChina life health foundationCapital equity investment company limitedChina life healthcare fundSector fundTechnological development zoneWuzhong biomedicine industrial park investment co ltd